Cargando…

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study

Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods...

Descripción completa

Detalles Bibliográficos
Autores principales: Pathadka, Swathi, Yan, Vincent K. C., Li, Xue, Tse, Gary, Wan, Eric Y. F., Lau, Hayden, Lau, Wallis C. Y., Siu, David C. W., Chan, Esther W., Wong, Ian C. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855850/
https://www.ncbi.nlm.nih.gov/pubmed/33553256
http://dx.doi.org/10.3389/fcvm.2020.602363
_version_ 1783646205266362368
author Pathadka, Swathi
Yan, Vincent K. C.
Li, Xue
Tse, Gary
Wan, Eric Y. F.
Lau, Hayden
Lau, Wallis C. Y.
Siu, David C. W.
Chan, Esther W.
Wong, Ian C. K.
author_facet Pathadka, Swathi
Yan, Vincent K. C.
Li, Xue
Tse, Gary
Wan, Eric Y. F.
Lau, Hayden
Lau, Wallis C. Y.
Siu, David C. W.
Chan, Esther W.
Wong, Ian C. K.
author_sort Pathadka, Swathi
collection PubMed
description Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45–0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45–0.77), all-cause mortality (HR 0.51; 95% CI, 0.36–0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70–1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39–1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age ≥ 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population.
format Online
Article
Text
id pubmed-7855850
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78558502021-02-04 Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study Pathadka, Swathi Yan, Vincent K. C. Li, Xue Tse, Gary Wan, Eric Y. F. Lau, Hayden Lau, Wallis C. Y. Siu, David C. W. Chan, Esther W. Wong, Ian C. K. Front Cardiovasc Med Cardiovascular Medicine Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45–0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45–0.77), all-cause mortality (HR 0.51; 95% CI, 0.36–0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70–1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39–1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age ≥ 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population. Frontiers Media S.A. 2021-01-20 /pmc/articles/PMC7855850/ /pubmed/33553256 http://dx.doi.org/10.3389/fcvm.2020.602363 Text en Copyright © 2021 Pathadka, Yan, Li, Tse, Wan, Lau, Lau, Siu, Chan and Wong. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Pathadka, Swathi
Yan, Vincent K. C.
Li, Xue
Tse, Gary
Wan, Eric Y. F.
Lau, Hayden
Lau, Wallis C. Y.
Siu, David C. W.
Chan, Esther W.
Wong, Ian C. K.
Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
title Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
title_full Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
title_fullStr Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
title_full_unstemmed Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
title_short Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
title_sort hospitalization and mortality in patients with heart failure treated with sacubitril/valsartan vs. enalapril: a real-world, population-based study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855850/
https://www.ncbi.nlm.nih.gov/pubmed/33553256
http://dx.doi.org/10.3389/fcvm.2020.602363
work_keys_str_mv AT pathadkaswathi hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT yanvincentkc hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT lixue hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT tsegary hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT wanericyf hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT lauhayden hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT lauwalliscy hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT siudavidcw hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT chanestherw hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy
AT wongianck hospitalizationandmortalityinpatientswithheartfailuretreatedwithsacubitrilvalsartanvsenalaprilarealworldpopulationbasedstudy